SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Stake in Aptose Biosciences

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a beneficial ownership of 4.99% in Aptose Biosciences Inc.'s common shares as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons,' beneficially own 1,025,267 common shares of Aptose Biosciences Inc.
• This ownership represents 4.99% of the total outstanding common shares of Aptose Biosciences Inc.
• The shares are held with shared voting power and shared dispositive power by both Armistice Capital, LLC and Steven Boyd.
• Armistice Capital, LLC is identified as an investment adviser, and Steven Boyd is identified as a control person and individual.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by an institutional investor, common in the financial industry to provide transparency on significant holdings in publicly traded companies. It does not provide specific insights into broader industry trends or competitive positioning beyond the fact of the investment.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can influence market perception and trading activity.

Key Dates

Keywords

Aptose Biosciences Inc., Armistice Capital LLC, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Shares, Investment Management, SEC Filing